» Articles » PMID: 19961336

Bone Turnover Markers and Prediction of Fracture: a Prospective Follow-up Study of 1040 Elderly Women for a Mean of 9 Years

Overview
Date 2009 Dec 8
PMID 19961336
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoporosis is characterized by compromised bone mass and strength, predisposing to an increased risk of fracture. Increased bone metabolism has been suggested to be a risk factor for fracture. The aim of this study was to evaluate whether baseline bone turnover markers are associated with long-term incidence of fracture in a population-based sample of 1040 women who were 75 years old (Malmö OPRA study). Seven bone markers (S-TRACP5b, S-CTX-I, S-OC[1-49], S-TotalOC, S-cOC, S-boneALP, and urinary osteocalcin) were measured at baseline and 1-year follow-up visit. During the mean follow-up of 9.0 years (range 7.4-10.9), 363 women sustained at least one fracture of any type, including 116 hip fractures and 103 clinical vertebral fractures. High S-TRACP5b and S-CTX-I levels were associated with increased risk of any fracture with hazard ratios [HRs (95% confidence interval)] of 1.16 (1.04-1.29) and 1.13 (1.01-1.27) per SD increase, respectively. They also were associated with increased risk of clinical vertebral fracture with HRs of 1.22 (1.01-1.48) and 1.32 (1.05-1.67), respectively. Markers were not associated with risk for hip fracture. Results were similar when we used resorption markers, including urinary osteocalcin, measured at the 1-year visit or an average of the two measurements. The HRs were highest for any fracture in the beginning of the follow-up period, 2.5 years from baseline. For vertebral fractures, the association was more pronounced and lasted for a longer period of time, at least for 5 years. In conclusion, elevated levels of S-TRACP5b, S-CTX-I, and urinary osteocalcin are associated with increased fracture risk for up to a decade in elderly women.

Citing Articles

Effects of total flavonoids of Rhizoma Drynariae on biochemical indicators of bone metabolism: a systematic review and meta-analysis.

Li W, Zhang Z, Li Y, Wu Z, Wang C, Huang Z Front Pharmacol. 2024; 15:1443235.

PMID: 39359242 PMC: 11445651. DOI: 10.3389/fphar.2024.1443235.


Therapeutic Intervention for Osteoporosis of Surgical Cases With Non-Vertebral Fractures for Three Years in a Newly Established Rural Hospital in Japan.

Nakayama M, Kiyota Y, Watanabe N, Yamanouchi K, Nakamura S, Takeshima K Cureus. 2024; 16(7):e63864.

PMID: 39100064 PMC: 11297664. DOI: 10.7759/cureus.63864.


Comparative analysis of bone turnover markers in bone marrow and peripheral blood: implications for osteoporosis.

Jiang C, Zhu S, Zhan W, Lou L, Li A, Cai J J Orthop Surg Res. 2024; 19(1):163.

PMID: 38429649 PMC: 10908102. DOI: 10.1186/s13018-024-04634-x.


Enhanced molecular release from elderly bone samples using collagenase I: insights into fatty acid metabolism alterations.

Malvandi A, Halilaj E, Faraldi M, Mangiavini L, Cristoni S, Leoni V J Transl Med. 2024; 22(1):143.

PMID: 38336738 PMC: 10858523. DOI: 10.1186/s12967-024-04948-8.


Osteoporosis: Investigations and Monitoring.

Panchagnula R, Amarnath S Indian J Orthop. 2023; 57(Suppl 1):70-81.

PMID: 38107808 PMC: 10721590. DOI: 10.1007/s43465-023-01019-w.